Novo defends diversification push as CEO eyes deals beyond obesity - CNBC


9/22/2026

Novo defends diversification push as CEO eyes deals beyond obesity  CNBCNovo targets blockbuster-heavy 2030 but share slump signals unease  Yahoo FinanceWegovy maker Novo shares slump as management grilled on pricing, M&A  reuters.comNovo’s prospects beyond weight-loss drugs look surprisingly lean  Financial TimesNovo’s Lack of Turnaround Details Disappoints, Hitting Shares  Bloomberg.com...

Original

Categories: Drugs | Health | Obesity

Tags: as | but | ceo | cnbc | deals | details | drugs | eyes | push | shares



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top